The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy

被引：27

作者：

Negredo, E ^{[1
]}

Clotet, B ^{[1
]}

Puig, J ^{[1
]}

Pérez-Alvarez, N ^{[1
]}

Ruiz, L ^{[1
]}

Romeu, J ^{[1
]}

Moltó, J ^{[1
]}

Rey-Joly, C ^{[1
]}

Blanco, J ^{[1
]}

机构：

[1] Univ Autonoma Barcelona, Germans Trias & Pujol Univ Hosp, Dept Internal Med, E-08193 Barcelona, Spain

来源：

AIDS | 2006年 / 20卷 / 04期

关键词：

D O I：

10.1097/01.aids.0000210617.90954.0e

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We conducted a pilot study to assess the effect of atorvastatin on HIV replication. Patients with stable HAART-controlled infection interrupted therapy and were randomly assigned to a control group or to start atorvastatin 40 or 80 mg/day. Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4.

引用

页码：619 / 621

页数：3

共 10 条

[1] Immunological and virological study of enfuvirtide-treated HIV-positive patients [J].

Barretina, J ;

Blanco, J ;

Bonjoch, A ;

Llano, A ;

Clotet, B ;

Esté, JA .

AIDS, 2004, 18 (12) :1673-1682

[2] INCREASED SUSCEPTIBILITY TO MOUSE HEPATITIS-VIRUS TYPE-3 (MHV3) INFECTION INDUCED BY A HYPERCHOLESTEROLEMIC DIET WITH INCREASED ADSORPTION OF MHV3 TO PRIMARY HEPATOCYTE CULTURES [J].

BRAUNWALD, J ;

NONNENMACHER, H ;

PEREIRA, CA ;

KIRN, A .

RESEARCH IN VIROLOGY, 1991, 142 (01) :5-15

[3] Lipid rafts and HIV-1: from viral entry to assembly of progeny virions [J].

Campbell, SM ;

Crowe, SM ;

Mak, J .

JOURNAL OF CLINICAL VIROLOGY, 2001, 22 (03) :217-227

[4] Statins inhibit HIV-1 infection by down-regulating Rho activity [J].

del Real, G ;

Jiménez-Baranda, S ;

Mira, E ;

Lacalle, RA ;

Lucas, P ;

Gómez-Moutón, C ;

Alegret, M ;

Peña, JM ;

Rodríguez-Zapata, M ;

Alvarez-Mon, M ;

Martínez-A, C ;

Mañes, S .

JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (04) :541-547

[5] Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1 [J].

Giguère, JF ;

Tremblay, MJ .

JOURNAL OF VIROLOGY, 2004, 78 (21) :12062-12065

[6] Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro [J].

Gower, TL ;

Graham, BS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1231-1237

[7] Evaluation of the anti-HIV activity of statins [J].

Moncunill, G ;

Negredo, E ;

Bosch, L ;

Vilarrasa, J ;

Witvrouw, M ;

Llanoa, A ;

Clotet, B ;

Esté, JA .

AIDS, 2005, 19 (15) :1697-1700

[8] Impact of HIV infection and HAART on serum lipids in men [J].

Riddler, SA ;

Smit, E ;

Cole, SR ;

Li, R ;

Chmiel, JS ;

Dobs, A ;

Palella, F ;

Visscher, B ;

Evans, R ;

Kingsley, LA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (22) :2978-2982

[9] Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy [J].

Sklar, PA ;

Masur, H ;

Grubb, JR ;

Voell, J ;

Witek, J ;

Ono, A ;

Freed, EO ;

Maldarelli, F .

AIDS, 2005, 19 (10) :1109-1111

[10]

Waters L, 2005, JAIDS-J ACQ IMM DEF, V39, P637

← 1 →